HMGB1-targeted anti-inflammatory rBox A gene therapy for viral airway infections and systemic inflammatory disease models.
mBio·
- DOI
- 10.1128/mbio.01819-26
- PMID
- 42635416
- PMCID
- —
- OpenAlex
- —
- Study type
- Journal article
- Publisher
- Publisher unavailable
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The authors frame the work as a candidate broad-spectrum, host-directed gene therapy and rapid-response countermeasure for HMGB1-driven inflammatory diseases and emerging respiratory pathogens, although only preclinical evidence is presented.
Structured evidence summary
Research question
Whether an inflammation-inducible adenoviral vector delivering recombinant HMGB1 Box A can reduce HMGB1-driven inflammation across infectious and non-infectious preclinical disease models.
Study design
Preclinical animal-model study optimizing an adenoviral gene-therapy construct and evaluating its therapeutic effect in multiple HMGB1-mediated infectious and non-infectious inflammation models.
Population and setting
Animal disease models including influenza-infected mice and cotton rats, plus additional HMGB1-mediated infectious and non-infectious inflammation models; no human subjects are described in the abstract.
Main findings
The optimized vector (AdV.C3-Tat/HIV-Box A) expressed rBox A under an inflammation-responsive C3 promoter, and therapeutic administration reduced lung and systemic inflammation in influenza models in mice and cotton rats, with protective and anti-inflammatory effects extended to multiple HMGB1-mediated disease models.
Public-health relevance
The authors frame the work as a candidate broad-spectrum, host-directed gene therapy and rapid-response countermeasure for HMGB1-driven inflammatory diseases and emerging respiratory pathogens, although only preclinical evidence is presented.
Important limitations
The abstract does not enumerate explicit limitations; it only notes general translational barriers for HMGB1/TLR4 antagonists (synthesis, dosing, delivery, off-target effects). This summary is limited to the supplied single-article abstract and metadata and requires the original paper for decision-grade interpretation.
GIDS interpretation
The article is discoverable as a preclinical gene-therapy candidate against HMGB1-mediated inflammation and influenza-related lung injury; no connection to a live surveillance signal can be inferred from the abstract alone.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 6 auditable classifier relationships to diseases, places, topics, and study design.